Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments
Frontiers in Endocrinology · 2023
DOI: 10.3389/fendo.2023.1125569 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Frontiers in Endocrinology, 2023. Verfasst von Marta Díaz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Diabetes Mellitus, Type 2, Metformin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Purpose
Follistatin is a glycoprotein that represses members of the transforming growth factor-β superfamily including activin. Higher follistatin levels have been associated with an increased risk for type 2 diabetes and with polycystic ovary syndrome (PCOS). In non-obese adolescent girls with PCOS, insulin sensitization results in a healthier endocrine-metabolic outcome than oral contraception (OC); we assessed whether those differences are underscored by changes in serum follistatin concentrations.
Methods
Circulating follistatin, endocrine-metabolic markers and hepato-visceral fat were measured longitudinally in 72 girls with PCOS [age, 16 years; body mass index (BMI), 23 Kg/m 2 ] randomized to receive PioFluMet [pioglitazone (7.5 mg/d), metformin (850 mg/d) and flutamide (62.5 mg/d), n=17]; EE-CA [an OC containing 35 µg ethinylestradiol (EE) and 2 mg cyproterone acetate (CA), n=17]; SPIOMET [Spironolactone (50 mg/d), pioglitazone (7.5 mg/d) and metformin (850 mg/d), n=18], or EE-LNG [an OC containing 20 µg EE and 100 mg levonorgestrel (LNG), n=20]. Twenty-eight age- and BMI-matched healthy girls served as controls.
Results
Pre-treatment follistatin levels were similar in PCOS and controls. OCs raised serum follistatin after 6 months (6.8-fold vs 2.5-fold for EE-CA and EE-LNG, respectively). Neither SPIOMET nor PioFluMet changed follistatin levels. Follistatin correlated negatively with high-molecular weight adiponectin and positively with mean serum insulin concentrations during an oral glucose tolerance test at baseline, and with liver fat after 6 months.
Conclusion
In girls with PCOS, follistatin levels rise significantly after 6 months on OCs and this increase associates to a worsening of markers of insulin resistance and to changes in liver fat.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrinology Department, Institut de Recerca Sant Joan de Déu, University of Barcelona, Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Instituto de Salud Carlos III, Madrid, Spain.
- University of Leuven, Leuven, Belgium.
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Díaz, M., de Zegher, F., & Ibáñez, L. (2023). Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2023.1125569
Vancouver
Díaz M, de Zegher F, Ibáñez L. Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments. Frontiers in Endocrinology. 2023. doi:10.3389/fendo.2023.1125569
BibTeX
@article{Daz2023,
author = {Díaz, Marta and de Zegher, Francis and Ibáñez, Lourdes},
title = {Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments},
journal = {Frontiers in Endocrinology},
year = {2023},
doi = {10.3389/fendo.2023.1125569}
}
EUVIMED